The Chandigarh-based Venus Remedies has informed that Indian Patent Office (IPO), Govt. of India has awarded the first ever injectable FDC Product Patent of POTENTOX.

This is the second patent of POTENTOX within 3 months of grant in South Korea.

Two years earlier, Venus had launched Potentox in Indian market. At present, the product has been used by more than 20,000 patients across India and has proved to be a big boon for ailing humanity.

The pharmaceutical company stated in a communiqué that this unique combination of a Cephalosporin with Aminoglycoside is a super specialty product indicated for the treatment of Hospital acquired pneumonia, Community acquired pneumonia and Febrile Neutropenia.

Recently, Venus Remedies' research product 'Mebatic' has got sales and manufacturing approvals from the Drugs Controller General of India (DCGI).

After touching an intraday high of Rs 292 on BSE, the scrip of the company finally settled the day at Rs 281, down half percent compared to yesterday's close.